Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
June 29, 2018 08:10 ET
|
Novartis Pharma AG
First CHMP opinion for a CAR-T cell therapy in two distinct indications - DLBCL in adults and B-cell ALL in children Marketing Authorization Application (MAA) based on landmark global CAR-T...
Novartis annonce son intention de solliciter l'approbation des actionnaires pour la scission à 100% d'Alcon, sa division de produits ophtalmologiques, et initie un rachat d'actions à hauteur d'USD ...
June 29, 2018 01:00 ET
|
Novartis Pharma AG
L'examen stratégique d'Alcon conclut qu'une scission à 100% serait dans l'intérêt des actionnaires et en ligne avec la stratégie de Novartis visant à se concentrer sur son activité pharmaceutique ...
Novartis gibt Absicht bekannt, die Genehmigung der Aktionäre für einen 100%igen Spin-off des Geschäfts mit ophthalmologischen Produkten von Alcon einzuholen und leitet gleichzeitig einen Aktienrück...
June 29, 2018 01:00 ET
|
Novartis Pharma AG
Die strategische Überprüfung von Alcon ergibt, dass ein 100%iger Spin-off im besten Interesse der Aktionäre ist und im Einklang mit der Strategie von Novartis steht, sich als Arzneimittelunternehmen...
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
June 29, 2018 01:00 ET
|
Novartis Pharma AG
Alcon strategic review concludes that 100% spinoff in best interest of shareholders and consistent with the Novartis strategy of focusing as a medicines company Planned spinoff would create...
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
June 01, 2018 08:00 ET
|
Novartis Pharma AG
Basel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)...
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
June 01, 2018 07:40 ET
|
Novartis Pharma AG
If approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package...
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
May 17, 2018 19:17 ET
|
Novartis Pharma AG
Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin...
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
May 02, 2018 16:05 ET
|
Novartis Pharma AG
Holzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing...
Novartis provides update on proposed acquisition of AveXis
May 01, 2018 01:00 ET
|
Novartis Pharma AG
Basel, May 1, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") applicable...
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
April 19, 2018 01:15 ET
|
Novartis Pharma AG
Basel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1,...